Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback